The big day begins! Vaccine production is days away

The coronavirus vaccine, produced by Pfizer and BioNTech, will begin administration on December 13 for the first time outside of trials

Prof. Dr. Ugur Sahin and Dr. The first application of the corona vaccine, developed by BioNTech, of which Ozlem Tureci is the founder, is expected to start on December 13 in the United States. The company expects the vaccine to be approved by the FDA for the big day.

Prof. Dr. Ugur Sahin and Dr. The company's most authoritative name, Pfizer CEO Albert Bourla, announced when BioNTech, founded by Ozlem Tureci, could make the first application of the vaccine developed by the American pharmaceutical company Pfizer other than trials.    

IT WILL START ON DECEMBER 13 AT THE EARLIEST

After US pharmaceutical giant Pfizer and BioNTech applied to the US Food and Drug Administration (FDA) for approval of their vaccine against Corona, which they announced was 95 percent effective, vaccination is expected to begin on December 13 at the earliest.

IT WILL BE DISTRIBUTED 24 HOURS AFTER APPROVAL

Moncef Slaoui, head of "Operation Warp Speed," the Trump administration's launch of the Covid-19 vaccine, told CNN television, "we plan to send the vaccine to vaccination centers within 24 hours of approval." said. Slaoui said he expected the approval to end as early as December 11 or 12. It is expected that vaccination procedures will first start with health workers.     

CEO ALBERT BOURLA ANNOUNCED IT AS A HISTORIC DAY

Albert Bourla, chief executive of US-based pharmaceutical giant Pfizer, said in a video released Friday: "Today is a historic day, today is a historic day for science and all of us. It has been 248 days since we announced our plans to cooperate with BioNTech until our application to the American food and Drug Administration today. From concept to licensing applications, we have always maintained our focus on safety, and we have worked at an undisclosed speed in our clinical development program." Pfizer was the first company to apply for a license for the coronavirus vaccine in the United States. According to a statement from Pfizer and BioNTech today, the vaccine candidate, known as 'BNT 162b2', could potentially be used in high-risk population groups in the United States in mid-December.